Topical Corticosteroid

Aka: Topical Corticosteroid, Topical Steroid, Clobetasol Propionate, Betamethasone Dipropionate, Triamcinolone Acetonide, Fluocinolone Acetonide, Hydrocortisone Cream, Hydrocortisone Topical, Halobetasol Propionate, Ultravate, Temovate, Diprolene, Diflorasone diacetate, Psorcon, Amcinonide, Cyclocort, Diprosone, Mometasone furoate, Elocon, Florone, Fluocinonide, Lidex, Maxiflor, Desoximetasone, Topicort, Halcinonide, Halog, Hydrocortisone valerate, Westcort, Kenalog, Flurandrenolide, Cordran, Betamethasone valerate, Valisone, Hydrocortisone butyrate, Locoid, Flucinolone Acetonide, Synalar, Alclometasone dipropionate, Aclovate, Desonide, Desowen

advertisement

II. Background

  1. Once daily dosing is as effective as 2-3 times daily dosing
    1. Increased frequency does not improve outcomes and decreases patient compliance
    2. Reapply after washing skin
    3. Green (2005) Br J Dermatol 152:130-41 [PubMed]
  2. Adjunctive measures: Occlusion
    1. Increases potency of steroid 10 fold
    2. Apply shower cap, plastic bag, vinyl suit, bandages or gloves
    3. Use for stubborn areas
  3. Vehicle
    1. See Preparation Bases
    2. Ointments (petroleum based)
      1. Thick, lubricating agents best applied to dry, hyperkeratotic smooth, non-hairy skin
      2. Least likely of topical agents to result in reaction (most inert with least additives)
      3. More potent than creams
      4. More greasy than creams
        1. Avoid on oozing lesions
        2. Avoid in intertriginous folds (e.g. axilla, groin) due to risk of maceration
        3. Avoid in moist or hot environment
    3. Creams
      1. Mixture of water and oils
      2. Less occlusive and more drying than ointments
      3. Often contain additives (e.g. Alcohol) which may be irritating
      4. Preservatives may result in Contact Dermatitis
    4. Lotions
      1. Higher water content than creams
      2. Least potent, least occlusive and least hydrating of vehicles
      3. Best used on hairy areas
    5. Gels
      1. Water-based with rapid drying from skin, and with minimal residue
      2. Sting when applied to inflamed or fissured skin
      3. Best used on hairy areas, or for its drying effect
    6. Foams
      1. Best used on scalp and other hairy regions (e.g. beard)
    7. Solutions, Shampoos and Sprays
      1. Best used on thick hair regions
      2. Many solutions are Alcohol based and may irritate inflamed or fissured skin
  4. Potency
    1. Potency is based on Vasoconstriction assay (degree of Vasoconstriction with steroid application)
    2. Tachyphylaxis (decreased effect with prolonged use) does not typically occur
    3. Ointments are typically considered more potent than creams and lotions
      1. However, efficacy is typically equal among Preparation Bases
      2. Feldman (2005) Curr Ther Res Clin Exp 66(3): 154-71 [PubMed]
      3. Zivkovich (2009) J Drugs Dermatol 8(6): 570-2 [PubMed]
    4. Topical Corticosteroids are divided into 7 classes
      1. Class 1: Very high potency
      2. Class 7: Very low potency
  5. Quantity to prescribe (10 day supply for twice daily dosing)
    1. See Topical Medication Quantity
    2. Face and neck
      1. Finger Tip units: 2.5
      2. Adult: 30 g
      3. Child: 15 g
      4. Infant: 7.5 g
    3. Hand (both sides)
      1. Finger Tip units: 1
      2. Adult: 15 g
      3. Child: 7.5 g
      4. Infant: 3.5 g
    4. Foot (both sides)
      1. Finger Tip units: 2
      2. Adult: 30 g
      3. Child: 15 g
      4. Infant: 7.5 g
    5. Arm
      1. Finger Tip units: 3
      2. Adult: 30 g
      3. Child: 15 g
      4. Infant: 7.5 g
    6. Leg
      1. Finger Tip units: 6
      2. Adult: 60 g
      3. Child: 30 g
      4. Infant: 15 g
    7. Trunk (front or back)
      1. Finger Tip units: 7
      2. Adult: 100 g
      3. Child: 50 g
      4. Infant: 25 g
    8. Body
      1. Adult: 300 g
      2. Child: 150 g
      3. Infant: 75 g
  6. Maximal Duration
    1. Face, groin and intertriginous areas (skin folds)
      1. Limit duration to 1-2 weeks at a time
    2. Very high potency (Class 1)
      1. Avoid use longer than 3 weeks
    3. Medium to high potency (Class 2-6)
      1. Avoid use longer than 12 weeks
    4. Low potency (Class 7)
      1. No specific maximal duration defined
  7. References
    1. Buys (2007) Am Fam Physician 75:523-8 [PubMed]

III. Risk Factors: Adverse Effects

  1. High potency Corticosteroids (esp. class 1-2)
  2. Young children
  3. Thin skin (e.g. face, intertriginous areas)
  4. Frequent or prolonged Topical Corticosteroid use

IV. Example: Lower cost, generic steroids

  1. Level 1: Clobetasol Propionate 0.05% ointment (price jump to $200 for 45 g in 2017)
  2. Level 2: Betamethasone Dipropionate 0.05% ointment
  3. Level 3: Betamethasone Dipropionate 0.05% cream
  4. Level 4: Triamcinolone Acetonide 0.1% cream
  5. Level 5: Triamcinolone Acetonide 0.1% lotion
  6. Level 6: Fluocinolone Acetonide 0.01% cream
  7. Level 7: Hydrocortisone 1% cream

V. Preparations: Level 1 (Ultra-High Potency)

  1. Betamethasone Dipropionate augmented (Diprolene) 0.05% cream and ointment
  2. Clobetasol Propionate (Temovate) 0.05% cream, ointment, lotion, gel, foam, solution, Shampoo, spray cream
  3. Diflorasone diacetate (Psorcon) 0.05% ointment
  4. Flucinonide (Lidex) 0.1% cream
  5. Flurandrenolide 4 mcg/cm2 tape
  6. Halobetasol Propionate (Ultravate) 0.05% cream and ointment

VI. Preparations: Level 2 (Very High Potency)

  1. Halcinonide (Halog) 0.1% cream
  2. Amcinonide (Cyclocort) 0.1% ointment
  3. Betamethasone Dipropionate augmented (Diprolene AF) 0.05% cream
  4. Betamethasone Dipropionate (Diprosone) 0.05% ointment
  5. Mometasone furoate (Elocon) 0.1% ointment
  6. Diflorasone diacetate (Florone) 0.05% ointment
  7. Fluocinonide (Lidex) 0.05% cream, gel, and ointment
  8. Diflorasone diacetate (Maxiflor) 0.05% ointment
  9. Desoximetasone (Topicort) 0.25% cream and ointment
  10. Desoximetasone (Topicort) 0.05% gel

VII. Preparations: Level 3 (High Potency)

  1. Halcinonide (Halog) 0.1% ointment, Emollient, cream
  2. Triamcinolone Acetonide (Aristocort A) 0.1% ointment
  3. Amcinonide (Cyclocort) 0.1% cream and lotion
  4. Betamethasone Dipropionate (Diprosone) 0.05% cream
  5. Diflorasone diacetate (Florone) 0.05% cream
  6. Fluocinonide (Lidex-E) 0.05% cream
  7. Diflorasone diacetate (Maxiflor) 0.05% cream
  8. Fluticasone propionate (Cutivate) 0.005% ointment

VIII. Preparations: Level 4 (Medium-High Potency)

  1. Hydrocortisone valerate (Westcort) 0.2% ointment
  2. Triamcinolone Acetonide (Kenalog) 0.1% cream
  3. Flurandrenolide (Cordran) 0.05% ointment
  4. Flucinolone Acetonide (Synalar) 0.025% ointment
  5. Mometasone furoate (Elocon) 0.1% cream

IX. Preparations: Level 5 (Medium Potency)

  1. Hydrocortisone valerate (Westcort) 0.2% cream
  2. Triamcinolone Acetonide (Kenalog) 0.1% lotion
  3. Flurandrenolide (Cordran) 0.05% cream
  4. Betamethasone Dipropionate (Diprosone) 0.05% lotion
  5. Betamethasone valerate (Valisone): 0.1% cream, lotion
  6. Hydrocortisone butyrate (Locoid) 0.1% cream
  7. Flucinolone Acetonide (Synalar) 0.025% cream
  8. Fluticasone propionate (Cutivate) 0.05% cream

X. Preparations: Level 6 (Low Potency)

  1. Alclometasone dipropionate (Aclovate) 0.05% ointment and cream
  2. Fluocinolone Acetonide (Synalar) 0.01% solution and cream
  3. Desonide (Desowen) 0.05% cream and ointment

XI. Preparations: Level 7 (Lowest Potency)

  1. Hydrocortisone 1%, 2.5% lotion, cream, ointment,

XII. Indications: Corticosteroid Potency Selection by Condition

  1. High potency Corticosteroids (Level 1-3)
    1. Alopecia Areata
    2. Atopic Dermatitis (refractory cases)
    3. Bullous Pemphigoid
    4. Dermatitis in regions of thick skin (e.g. palms, soles)
    5. Discoid Lupus
    6. Dyshidrotic Eczema (esp. hands, severe cases)
    7. Eczematous Dermatitis (severe cases)
    8. Hyperkeratotic Eczema
    9. Labial Adhesions
    10. Lichen Planus
    11. Lichen Sclerosus (skin)
    12. Lichen Simplex Chronicus
    13. Melasma
    14. Nummular Eczema
    15. Poison Ivy (severe cases)
    16. Psoriasis
    17. Vitiligo
  2. Medium potency Corticosteroids (Level 4-5)
    1. Asteatotic Eczema
    2. Atopic Dermatitis
    3. Dermatitis (severe)
    4. Infantile Acropustulosis
    5. Intertrigo (short-term use for severe cases)
    6. Lichen Sclerosus (vulvar)
    7. Nummular Eczema
    8. Perianal inflammation (severe cases)
    9. Scabies (only after the anti-Scabies agent has been used)
    10. Seborrheic Dermatitis
    11. Severe Intertrigo
    12. Stasis Dermatitis
  3. Low potency Corticosteroids (Level 6-7)
    1. Dermatitis (face, Eyelids, diaper area)
    2. Intertrigo
    3. Perianal inflammation
    4. Phimosis
  4. References
    1. Ference (2009) Am Fam Physician 79(2): 135-40 [PubMed]

XIII. Indications: Corticosteroid Potency Selection by Distribution

  1. Low potency Topical Corticosteroids
    1. Face
    2. Groin
    3. Intertriginous areas
  2. Mid-potency Topical Corticosteroids
    1. Thin skin trunk areas
    2. Extremity lesions
  3. High potency Topical Corticosteroids
    1. Thick skin trunk areas
    2. Extremity lesions
  4. Very high or super-potent Corticosteroids
    1. Very thick-skinned areas
    2. Palms and soles

XIV. Adverse Effects: Topical Corticosteroids

  1. Percutaneous absorption with systemic steroid effects
    1. Systemic effects are uncommon with Topical Corticosteroids
    2. Risk Factors for systemic effects
      1. Very high potency and high potency Topical Corticosteroids (level 1-3)
      2. Prolonged use of higher potency Topical Corticosteroids >2-4 weeks
      3. Large surface area of Topical Corticosteroid application
      4. High potency Corticosteroid on thin skin (e.g. face, axilla, groin)
      5. Children and Elderly (higher absorption)
    3. Mitigation of systemic effects
      1. Limit high potency Corticosteroids to 2-4 weeks of use
      2. Consider pulse dosing of Topical Corticosteroid (2 weeks on, 1 week off)
      3. When appropriate, use lower potency Corticosteroids
    4. Systemic Corticosteroid Effects
      1. Cushing Syndrome
      2. Adrenal suppression
      3. Growth Delay
      4. Steroid-Induced Hyperglycemia
      5. Aseptic Necrosis of the Femoral Head
      6. Hypertension
      7. Peripheral Edema
  2. Skin atrophy
    1. Skin fragility
    2. Easy Bruising
    3. Pigment change (Hypopigmentation, Hyperpigmentation)
    4. Petechiae, Purpura and Telangiectasias
    5. Skin Ulcers
    6. Striae formation
  3. Rebound papular dermatitis after medium-high potency
    1. Avoid high potency steroid on genital or face
  4. Secondary or provoked Skin Infections
    1. Masked Tinea Infection
    2. Granuloma gluteale infantum
  5. Eye affects (if exposed)
    1. Glaucoma
    2. Cataracts
  6. Corticosteroid withdrawal effects (rebound inflammation after stopping steroid)
    1. Most common on the face and genitalia
    2. Erythema, edema and skin Scaling
    3. Stinging and burning
    4. Papules and Pustules
  7. Other effects
    1. Acne Rosacea
    2. Acne Vulgaris
    3. Contact Dermatitis
    4. Delayed Wound Healing
    5. Hypertrichosis
    6. Periocular Dermatitis
    7. Photosensitivity
    8. Superficial Folliculitis
  8. References
    1. Hengge (2006) J Am Acad Dermatol 54(1): 1-15 [PubMed]

XV. Safety

  1. Topical Corticosteroids appear safe in pregnancy and Lactation
    1. Use the lowest potency effective Topical Steroid
      1. Hydrocortisone 0.5 to 1% applied twice daily for up to 10 days (most safety data)
    2. Avoid high potency steroids and prolonged steroid use
      1. Risk of hypothalamic-pituitary-adrenal axis suppression
      2. May provoke Hyperglycemia and Hypertension
    3. References
      1. Chi (2015) Cochrane Database Syst Rev (10): CD007346 [PubMed]
      2. Hengge (2006) J Am Acad Dermatol 54(1): 1-15 [PubMed]

XVI. References

  1. (2021) Presc Lett 28(5): 29
  2. (2018) Presc Lett 25(1): 5
  3. Kaplan (2001) CMEA Medicine Lecture, San Diego
  4. Stacey (2021) Am Fam Physician 103(6): 337-43 [PubMed]

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Topical Corticosteroid." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies

Cost: Medications

mometasone furoate (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing)
MOMETASONE FUROATE 0.1% CREAM Generic $0.44 per gram
MOMETASONE FUROATE 0.1% OINT Generic $0.28 per gram
MOMETASONE FUROATE 0.1% SOLN Generic $0.32 per ml
MOMETASONE FUROATE 50 MCG SPRY Generic $2.10 per gram
fluocinonide (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing)
FLUOCINONIDE 0.05% CREAM Generic $0.56 per gram
FLUOCINONIDE 0.05% GEL Generic $1.25 per gram
FLUOCINONIDE 0.05% OINTMENT Generic $0.30 per gram
FLUOCINONIDE 0.05% SOLUTION Generic $0.28 per ml
FLUOCINONIDE 0.1% CREAM Generic $0.33 per gram
FLUOCINONIDE-E 0.05% CREAM Generic $1.12 per gram
desoximetasone (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing)
DESOXIMETASONE 0.05% CREAM Generic $2.61 per gram
DESOXIMETASONE 0.05% OINTMENT Generic $3.34 per gram
DESOXIMETASONE 0.25% CREAM Generic $0.62 per gram
DESOXIMETASONE 0.25% OINTMENT Generic $0.62 per gram
DESOXIMETASONE 0.25% SPRAY Generic $1.44 per ml
kenalog (on 3/23/2022 at Medicaid.Gov Survey of pharmacy drug pricing)
KENALOG-10 50 MG/5 ML VIAL $2.32 per ml
KENALOG-40 200 MG/5 ML VIAL $9.10 per ml
KENALOG-40 40 MG/ML VIAL Generic $5.86 per ml
KENALOG-40 400 MG/10 ML VIAL $6.80 per ml
desonide (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing)
DESONIDE 0.05% CREAM Generic $0.49 per gram
DESONIDE 0.05% LOTION Generic $1.38 per ml
DESONIDE 0.05% OINTMENT Generic $0.66 per gram
FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information. GoodRx is another tool for finding lower drug prices.

Ontology: Beclomethasone Dipropionate (C0004906)

Definition (NCI) The dipropionate ester of a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.
Definition (PDQ) The dipropionate salt of a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39272&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39272&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C299" NCI Thesaurus)
Concepts Pharmacologic Substance (T121) , Steroid (T110)
MSH D001507
SnomedCT 116575004, 331007007, 38516009, 320477002, 331779003, 320620006
LNC LP35865-2, MTHU017342
English Dipropionate, Beclomethasone, Beclomethasone diprop [nose], Beclomethasone diprop [resp], Beclomethasone diprop [skin], (11beta,16beta)-9-Chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione, Beclomethasone Dipropionate, Beclomethasone diprop [resp 2], Beclomethasone dipropionate [respiratory use 2], Beclomethasone dipropionate [nose], Beclomethasone dipropionate [respiratory use], (11beta,16beta)-9-Chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione Dipropionate, beclomethasone dipropionate (medication), topical steroids beclomethasone dipropionate, Beclometasone dipropionate, beclomethasone dipropionate, BECLOMETHASONE DIPROPIONATE, Beclomethasone Dipropionate [Chemical/Ingredient], Beclomethasone dipropionate preparation, Beclometasone dipropionate [nose], Beclometasone dipropionate [respiratory use], Beclomethasone dipropionate [respiratory use] (product), Beclomethasone dipropionate [nose] (product), Beclometasone diprop [skin], Beclometasone dipropionate [respiratory use 2], Beclomethasone dipropionate [respiratory use 2] (product), Beclomethasone diprop [skin] (product), Beclomethasone dipropionate preparation (product), Beclometasone dipropionate preparation, Beclomethasone dipropionate, Beclomethasone dipropionate (substance), BDP, Beclomethasone diprop [skin] (substance), Beclomethasone dipropionate [nose] (substance), Beclomethasone dipropionate [respiratory use 2] (substance), Beclomethasone dipropionate [respiratory use] (substance), Beclomethasone dipropionate preparation (substance)
Spanish preparado de dipropionato de beclometasona, Dipropionato Beclometasona, dipropionato de beclometasona [uso respiratorio 2], dipropionato de beclometasona [uso respiratorio], dipropionato de beclometasona (uso nasal) (producto), dipropionato de beclometasona (uso dermatológico), dipropionato de beclometasona [uso respiratorio] (producto), dipropionato de beclometasona [uso respiratorio 2] (producto), dipropionato de beclometasona (uso nasal), preparado con dipropionato de beclometasona (producto), preparado con dipropionato de beclometasona, dipropionato de beclometasona (uso dermatológico) (producto), dipropionato de beclometasona (nasal) (producto), dipropionato de beclometasona (nasal), dipropionato de beclometasona (piel) (producto), dipropionato de beclometasona (piel), dipropionato de beclometasona (sustancia), dipropionato de beclometasona, preparado de dipropionato de beclometasona (producto), preparado de dipropionato de beclometasona (sustancia)
Portuguese Dipropionato de Beclometasona
German Beclomethasondiproprionat
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: Fluocinolone Acetonide (C0016298)

Definition (NCI) The acetonide salt form of fluocinolone, a synthetic fluorinated corticosteroid with antiinflammatory, antipruritic and vasoconstrictive properties. Fluocinolone is a glucocorticoid receptor agonist that binds to cytoplasmic glucocorticoid receptors and subsequently translocates to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both are potent mediators of inflammation. Fluocinolone exerts its vasoconstrictive effect through inhibition of nitric oxide synthase, thereby blocking nitric oxide production and effectively diminishing the effect of nitric oxide on vascular smooth muscles leading to reduced blood flow.
Definition (MSH) A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732)
Concepts Pharmacologic Substance (T121) , Steroid (T110)
MSH D005446
SnomedCT 54147006, 331918005, 396059004
English Acetonide, Fluocinolone, Acetonide, Fluortriamcinolone, Fluortriamcinolone Acetonide, Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-, (6alpha,11beta,16alpha)-6,9-Difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione, fluocinolone acetonide, Fluocinolone Acetonide, topical steroids fluocinolone acetonide, fluocinolone acetonide (medication), Fluocinolone Acetonide [Chemical/Ingredient], FLUOCINOLONE ACETONIDE, Fluocinolone acetonide (product), Fluocinolone acetonide, Fluocinolone acetonide (substance), Fluocinolone acetonide [dup] (substance)
Swedish Fluokinolonacetonid
Czech fluocinolonacetonid
Finnish Fluosinoloniasetonidi
Russian SINAFLAN, FLUORTRIAMTSINOLONA ATSETONID, FLIUOTSINOLONA ATSETONID, FTORTRIAMTSINOLONA ATSETONID, СИНАФЛАН, ФЛУОРТРИАМЦИНОЛОНА АЦЕТОНИД, ФЛЮОЦИНОЛОНА АЦЕТОНИД, ФТОРТРИАМЦИНОЛОНА АЦЕТОНИД
Italian Fluortriamcinolone acetonide, Fluocinolone acetonide
Croatian FLUOCINOLON-ACETONID
Polish Flucinar
Japanese エスアランF, フルオシノロンアセトニド, コリフェート, フルオルトリアムシノロンアセトニド, フルコートL, フルコート, フルゾン, フルベアン, フルポロン, ポリシラール
Spanish acetonida de fluocinolona (producto), acetonida de fluocinolona (sustancia), acetonida de fluocinolona, acetonuro de fluocinolona (producto), acetonuro de fluocinolona (sustancia), acetonuro de fluocinolona, Acetonida de Fluortriamcinolona, Fluocinolona Acetonida
Portuguese Fluocinolona-Acetonida, Acetonida de Fluocinolona, Fluocinolona Acetonida, Fluortriamcinolona Acetonida
French Fluocinolone acétonide
German Fluocinolonacetonid, Fluortriamcinolon-Acetonid
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: Hydrocortisone topical preparation (C0020269)

Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
SnomedCT 91413005
English topical steroids hydrocortisone, hydrocortisone (topical), hydrocortisone (topical) (medication), topical hydrocortisone, hydrocortisone topical, Topical hydrocortisone, Hydrocortisone topical preparation (product), Hydrocortisone topical preparation, Hydrocortisone topical preparation, NOS, Hydrocortisone topical preparation (substance)
Spanish preparado tópico con hidrocortisona (producto), preparado tópico con hidrocortisona, preparado tópico de hidrocortisona (producto), preparado tópico de hidrocortisona (sustancia), preparado tópico de hidrocortisona
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: Triamcinolone Acetonide (C0040866)

Definition (NCI) The acetonide salt form of triamcinolone, a synthetic glucocorticosteroid with immunosuppressive and anti-inflammatory activity. Triamcinolone acetonide binds to specific cytosolic glucocorticoid receptors and subsequently interacts with glucocorticoid receptor response element on DNA and alters gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished.
Definition (MSH) An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.
Concepts Pharmacologic Substance (T121) , Steroid (T110)
MSH D014222
SnomedCT 126157006, 7155009, 329998000, 332006001, 331073005, 395913005
LNC LP35874-4, MTHU018765
English Acetonide, Triamcinolone, Triamcinolone Acetonide, Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11beta,16alpha)-, Triamcinolone aceton [mskel], Triamcinolone acetonide [skin], 9-alpha-Fluoro-11-beta,21-dihydroxy-16-alpha-isopropylidenedioxy-1,4-pregnadiene,3,20-dione, triamcinolone acetonide, Triamcinolone acetate [nose], Triamcinolone acetonide [musculoskeletal use], triamcinolone acetonide (medication), topical steroids triamcinolone acetonide, TRIAMCINOLONE ACETONIDE, Triamcinolone Acetonide [Chemical/Ingredient], acetonide triamcinolone, Triamcinolone acetonide preparation (product), Triamcinolone acetonide (product), Triamcinolone acetonide preparation, Triamcinolone acetate [nose] (product), Triamcinolone acetonide [skin] (product), Triamcinolone acetonide [musculoskeletal use] (product), Triamcinolone acetonide, Triamcinolone acetonide (substance), Triamcinolone acetate [nose] (substance), Triamcinolone acetonide [musculoskeletal use] (substance), Triamcinolone acetonide [skin] (substance), Triamcinolone acetonide preparation (substance)
Swedish Triamcinolonacetonid
Czech triamcinolonacetonid
Finnish Triamsinoloniasetonidi
Russian TRIAMTSINOLONA ATSETONID, KENALOG, КЕНАЛОГ, ТРИАМЦИНОЛОНА АЦЕТОНИД
Japanese トリアムシノロンアセトニド
Polish Acetonid triamcynolonu
Spanish acetonida de triamcinolona (uso dermatológico) (producto), acetonida de triamcinolona [uso musculoesquelético] (producto), acetonida de triamcinolona (producto), acetato de triamcinolona (uso nasal), preparado de acetonida de triamcinolona, acetato de triamcinolona (uso nasal) (producto), acetonida de triamcinolona (uso dermatológico), preparado de acetonida de triamcinolona (producto), acetonida de triamcinolona [uso musculoesquelético], acetato de triamcinolona (nasal) (producto), acetato de triamcinolona (nasal), acetonida de triamcinolona (piel) (producto), acetonida de triamcinolona (piel), acetonida de triamcinolona (sustancia), acetonida de triamcinolona, acetonuro de triamcinolona (producto), acetonuro de triamcinolona (sustancia), acetonuro de triamcinolona, preparado de acetonida de triamcinolona (sustancia), Triamcinolona Acetonida
French Triamcinolone acétonide
German Triamcinolonacetonid
Italian Triamcinolone acetonide
Portuguese Triancinolona Acetonida
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: Clobetasol Propionate (C0055895)

Definition (NCI) The propionate salt form of clobetasol, a topical synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2.
Definition (MSH) This is the form in trademark preparations.
Concepts Pharmacologic Substance (T121) , Steroid (T110)
MSH D002990
SnomedCT 331854005, 32197004
English Clobetasol Propionate, Clobetasol 17-Propionate, clobetasol propionate, CLOBETASOL PROPIONATE, clobetasol propionate (medication), topical steroids clobetasol propionate, Clobetasol Propionate [Chemical/Ingredient], clobetasol 17-propionate, Clobetasol propionate, Clobetasol propionate (substance), Clobetasol propionate [dup] (substance), Clobetasol 17 Propionate
Spanish propionato de clobetasol (sustancia), propionato de clobetasol
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: diflorasone diacetate (C0057992)

Definition (NCI) The acetate salt form of diflorasone, a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. Like other glucocorticoids, diflorasone enters the cell by diffusion across the cell membrane and binds to the glucocorticoid receptor (GR) in the cytoplasm. The receptor complex subsequently translocates to the nucleus and activates or represses genes by interacting with short, palindromic DNA sequences called glucocorticoid response element (GRE). Gene activation leads to the exertion of anti-inflammatory effects, e.g. upregulation of IkappaB, while gene repression inhibits production of pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-2 and IL-6, thereby preventing activation of cytotoxic T-lymphocytes.
Concepts Pharmacologic Substance (T121) , Steroid (T110)
MSH C014477
SnomedCT 38446009
English 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-Diacetate, 6alpha-Fluorobetamethasone-17,21 Diacetate, Diflorasone Diacetate, topical steroids diflorasone diacetate, diflorasone diacetate (medication), diflorasone diacetate, diflorasone diacetate [Chemical/Ingredient], DIFLORASONE DIACETATE, Diflorasone diacetate, Diflorasone diacetate (substance)
Spanish diacetato de diflorasona (sustancia), diacetato de diflorasona
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: hydrocortisone valerate (C0063079)

Definition (NCI) The valerate salt form of hydrocortisone, a synthetic glucocorticoid receptor agonist with antiinflammatory, antipruritic and vasoconstrictive effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2. Lack of phospholipase A2 prevents the release of arachidonic acid, precursor for inflammatory mediator prostaglandins and leukotrienes, from the cell membrane. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.
Concepts Pharmacologic Substance (T121) , Steroid (T110)
MSH C038363
SnomedCT 51612003
English hydrocortisone valerate, 11beta,17,21-Trihydroxypregn-4-ene-3,20-dione 17-Valerate, Hydrocortisone Valerate, topical steroids hydrocortisone valerate, hydrocortisone valerate (medication), HYDROCORTISONE VALERATE, hydrocortisone valerate [Chemical/Ingredient], Hydrocortisone valerate (substance), Hydrocortisone valerate, Hydrocortisone valerate, NOS
Spanish valerato de hidrocortisona (sustancia), valerato de hidrocortisona
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: mometasone furoate (C0066700)

Definition (NCI) The furoate salt form of mometasone, a synthetic topical glucocorticosteroid receptor agonist with anti-inflammatory, anti-pruritic and vasoconstrictive properties. Mometasone furoate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.. Specifically, mometasone furoate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from phospholipid membrane by phospholipase A2.
Definition (NCI_NCI-GLOSS) A drug that is used in a cream to treat certain skin conditions and in a nasal spray to treat sinus problems caused by allergies. It is being studied as a way to treat inflammation of the skin caused by radiation therapy. Elocon is a type of corticosteroid.
Definition (PDQ) The furoate salt form of mometasone, a synthetic topical glucocorticosteroid receptor agonist with anti-inflammatory, anti-pruritic and vasoconstrictive properties. Mometasone furoate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.. Specifically, mometasone furoate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from phospholipid membrane by phospholipase A2. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=531049&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=531049&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29268" NCI Thesaurus)
Concepts Pharmacologic Substance (T121) , Steroid (T110)
MSH C053915
SnomedCT 43059007, 332042009, 395802006
English mometasone furoate, (11beta,16alpha)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione, Mometasone Furoate, topical steroids mometasone furoate, mometasone furoate (medication), MOMETASONE FUROATE, mometasone furoate [Chemical/Ingredient], furoate mometasone, Mometasone furoate (product), Mometasone furoate, Mometasone furoate (substance), Mometasone furoate [dup] (substance)
Spanish furoato de mometasona (producto), furoato de mometasona (sustancia), furoato de mometasona
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: halobetasol propionate (C0098735)

Definition (NCI) The propionate salt form of halobetasol, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictor activities. Halobetasol, a topical steroid, diffuses across cell membranes to interact with cytoplasmic corticosteroid receptors located in both the dermal and intradermal cells, thereby activating gene expression of anti-inflammatory proteins mediated via corticosteroid receptor response element. Specifically, this agent induces phospholipase A2 inhibitory proteins, which inhibit the release of arachidonic acid, thereby inhibiting the biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes. As a result, halobetasol reduces edema, erythema, and pruritus through its cutaneous effects on vascular dilation and permeability.
Concepts Pharmacologic Substance (T121) , Steroid (T110)
MSH C064466
SnomedCT 126085005, 126149008
English 6-fluoroclobetasol 17-propionate, 21-Chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate, Halobetasol Propionate, halobetasol propionate (medication), topical steroids halobetasol propionate, HALOBETASOL PROPIONATE, Halobetasol propionate, Halobetasol propionate (substance), Halobetasol propionate preparation (product), Halobetasol propionate preparation, Halobetasol propionate preparation (substance), 6 alpha-fluoroclobetasol 17-propionate, halobetasol propionate
Spanish propionato de halobetasol (producto), preparado con propionato de halobetasol (producto), preparado con propionato de halobetasol, preparado de propionato de halobetasol (producto), preparado de propionato de halobetasol (sustancia), preparado de propionato de halobetasol, propionato de halobetasol (sustancia), propionato de halobetasol
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: Topical form corticosteroids (C0304604)

Definition (NCI) Any synthetic steroid derivative exhibiting the same function as the naturally occurring corticosteroid hormone, formulated for topical application. Topical corticosteroids are applied to the skin where it exerts its effect, however, corticosteroids can be absorbed systemically after being applied locally. Topical corticosteroids are mainly used for the localized treatment of inflammation of the skin and help relieve symptoms such as itching, swelling and redness.
Concepts Pharmacologic Substance (T121)
SnomedCT 31057002, 331645009
English Topical corticosteroids, Topical corticosteroid preparation, Topical Corticosteroids, Topical Corticosteroid, corticosteroids topical, topical corticosteroids, corticosteroid topical, topical corticosteroid, Topical corticosteroid preparation (product), Topical form corticosteroid preparation, Topical form corticosteroids (product), Topical form corticosteroids, Topical corticosteroid, NOS, Topical corticosteroid preparation (substance), Topical corticosteroids (product), Topical corticosteroids (substance)
Spanish corticoesteroide de uso tópico (producto), corticosteroide, forma farmacéutica tópica (producto), corticoesteroide de uso tópico, corticoide, forma farmacéutica tópica, corticosteroide, forma farmacéutica tópica, preparado con corticosteroide, tópico, preparado con corticosteroide, tópico (producto), corticoesteroide tópico, corticosteroide tópico (producto), corticosteroide tópico (sustancia), corticosteroide tópico, corticosteroides tópicos (producto), corticosteroides tópicos
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: Hydrocortisone creams (C0352305)

Concepts Clinical Drug (T200)
SnomedCT 331646005
English hydrocortisone creams, hydrocortisone cream, Hydrocortisone creams, Hydrocortisone creams (product), Hydrocortisone creams (substance)
Spanish crema con hidrocortisona, hidrocortisona, crema (producto), hidrocortisona, crema
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: Hydrocortisone butyrate (C0352536)

Definition (NCI) The butyrate salt form of hydrocortisone, a synthetic glucocorticoid receptor agonist with antiinflammatory, antipruritic and vasoconstrictive effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2. Lack of phospholipase A2 prevents the release of arachidonic acid, precursor for inflammatory mediator prostaglandins and leukotrienes, from the cell membrane. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leading to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.
Concepts Pharmacologic Substance (T121) , Steroid (T110)
SnomedCT 331982002, 50665003
English 11-beta,17-alpha,21-Trihydroxy-4-pregnene-3,20-dione 17-alpha-butyrate, Hydrocortisone Butyrate, topical steroids hydrocortisone butyrate, hydrocortisone butyrate (medication), HYDROCORTISONE BUTYRATE, hydrocortisone butyrate, Hydrocortisone butyrate, Hydrocortisone butyrate (substance), Hydrocortisone butyrate, NOS, Hydrocortisone butyrate [dup] (substance)
Spanish butirato de hidrocortisona (sustancia), butirato de hidrocortisona
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: Elocon (C0720180)

Concepts Pharmacologic Substance (T121) , Steroid (T110)
MSH C053915
English Elocon, elocon
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: Maxiflor (C0721607)

Concepts Pharmacologic Substance (T121) , Steroid (T110)
MSH C014477
English Maxiflor, Allergan brand of diflorasone diacetate
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: Psorcon (C0722905)

Concepts Pharmacologic Substance (T121) , Steroid (T110)
MSH C014477
English Psorcon, psorcon, Dermik brand 2 of diflorasone diacetate
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: Betamethasone valerate (C0750848)

Definition (NCI) The 17-valerate ester of betamethasone, a synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory actions. Betamethasone valerate binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.
Definition (MSH) The 17-valerate derivative of BETAMETHASONE. It has substantial topical anti-inflammatory activity and relatively low systemic anti-inflammatory activity.
Concepts Pharmacologic Substance (T121) , Steroid (T110)
MSH D001624
SnomedCT 396005002, 66854004
English 17-Valerate, Betamethasone, Betamethasone 17 Valerate, Flubenisolonvalerate, Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-17-((1-oxopentyl)oxy)-, (11beta,16beta)-, betamethasone valerate, BETAMETHASONE VALERATE 17, betamethasone valerate (medication), topical steroids betamethasone valerate, BETAMETHASONE VALERATE, Betamethasone Valerate, Betamethasone 17-Valerate, Valerate, Betamethasone, Betamethasone Valerate [Chemical/Ingredient], Betamethasone valerate, Betamethasone valerate product, Betamethasone valerate (product), Betamethasone valerate (substance)
Swedish Betametason 17-valerat
Czech betamethason 17-valerát
Finnish Beetametasoni-17-valeraatti
Italian Flubenisolone valerato, Betametasone 17-valerato, Betametasone valerato
Russian FLUBENIZOLONVALERAT, BETAMETAZONA-17-VALERAT, 17-ВАЛЕРАТ БЕТАМЕТАЗОНА, БЕТАМЕТАЗОНА ВАЛЕРАТ, БЕТАМЕТАЗОНА-17-ВАЛЕРАТ, BETAMETAZONA VALERAT, 17-VALERAT BETAMETAZONA, ФЛУБЕНИЗОЛОНВАЛЕРАТ
Japanese フルベニソロンバレレート, 吉草酸ベタメタゾン, 17-吉草酸ベタメタゾン
German BETAMETHASON VALERAT 17, Betamethason-17-Valerat, Flubenisolonvalerat
Polish 17-walerianian betametazonu
French Bétaméthasone valérate-17, Bétaméthasone valérate, Valérate de bétaméthasone
Spanish 17-Valerato de Betametasona, Not Translated[Betamethasone Valerate], valerato de betametasona (producto), valerato de betametasona (sustancia), valerato de betametasona, Flubenisolonvalerato
Portuguese 17-Valerato de Betametasona, Not Translated[Betamethasone Valerate], Flubenisolonvalerato
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: topical steroids (C2064827)

Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
English topical steroids (medication), topical steroids
Derived from the NIH UMLS (Unified Medical Language System)

Related Topics in Pharmacology

advertisement

2025 Family Practice Notebook, LLC. Terms | Privacy | About | Site Map | Newsletter | Blog

Footer Site Logo